- Home
- AIFF vs MRSN Comparison
AIFF vs MRSN Comparison
Compare AIFF & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIFF
- MRSN
- Stock Information
- Founded
- AIFF 2006
- MRSN 2001
- Country
- AIFF United States
- MRSN United States
- Employees
- AIFF N/A
- MRSN N/A
- Industry
- AIFF
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- AIFF
- MRSN Health Care
- Exchange
- AIFF NYSE
- MRSN Nasdaq
- Market Cap
- AIFF 37.9M
- MRSN 40.7M
- IPO Year
- AIFF N/A
- MRSN 2017
- Fundamental
- Price
- AIFF $3.03
- MRSN $0.35
- Analyst Decision
- AIFF
- MRSN Strong Buy
- Analyst Count
- AIFF 0
- MRSN 5
- Target Price
- AIFF N/A
- MRSN $5.75
- AVG Volume (30 Days)
- AIFF 2.8M
- MRSN 3.1M
- Earning Date
- AIFF 08-18-2025
- MRSN 08-12-2025
- Dividend Yield
- AIFF N/A
- MRSN N/A
- EPS Growth
- AIFF N/A
- MRSN N/A
- EPS
- AIFF N/A
- MRSN N/A
- Revenue
- AIFF $139,000.00
- MRSN $34,006,000.00
- Revenue This Year
- AIFF N/A
- MRSN N/A
- Revenue Next Year
- AIFF N/A
- MRSN $1.03
- P/E Ratio
- AIFF N/A
- MRSN N/A
- Revenue Growth
- AIFF N/A
- MRSN N/A
- 52 Week Low
- AIFF $1.86
- MRSN $0.26
- 52 Week High
- AIFF $17.20
- MRSN $2.83
- Technical
- Relative Strength Index (RSI)
- AIFF 50.69
- MRSN 52.71
- Support Level
- AIFF $2.93
- MRSN $0.32
- Resistance Level
- AIFF $3.08
- MRSN $0.38
- Average True Range (ATR)
- AIFF 0.17
- MRSN 0.03
- MACD
- AIFF 0.01
- MRSN 0.01
- Stochastic Oscillator
- AIFF 57.14
- MRSN 69.00
About AIFF FIREFLY NEUROSCIENCE INC
Firefly Neuroscience Inc is an AI company developing neuroscientific solutions that improve outcomes for patients with mental illnesses and cognitive disorders. It is focused on the commercialization of its Brain Network Analytics (BNA) software platform (the "BNA Platform")and the discovery and clinical development of biomarkers that support outcomes for people suffering from mental illnesses and cognitive disorders. The Company has one reportable segment: the BNA platform. The Company derives revenue from North America.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.